SCYNEXIS

$1.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-2.17%) As of 1:49 PM EDT today
-$0.02 (-2.17%) Today

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, ETFs, and crypto commission-free!

About SCYX

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Read More The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Employees
24
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
64.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
192.37K
High Today
$1.16
Low Today
$1.12
Open Price
$1.14
Volume
113.42K
52 Week High
$1.90
52 Week Low
$0.35

Collections

SCYX Earnings

-$0.46
-$0.30
-$0.15
$0.01
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 12, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.